Tenner-Racz K, Stellbrink H J, van Lunzen J, Schneider C, Jacobs J P, Raschdorff B, Grosschupff G, Steinman R M, Racz P
Medical Department, Eppendorf University, 20251 Hamburg, Germany.
J Exp Med. 1998 Mar 16;187(6):949-59. doi: 10.1084/jem.187.6.949.
The efficacy of triple drug therapy for HIV-1 infection encourages its early use to prevent damage to the immune system. We monitored the effects of such therapy on 12 patients with 14-75-mo histories of minimal disease, i.e., CD4+ counts constantly >500/microl and little or no lymph node enlargement. In this way, we could first determine the extent of viral replication and immunoarchitectural changes in unenlarged nodes early in disease, and second follow the response to triple therapy in plasma and lymphoid tissue in tandem. As is known for lymph nodes with more advanced disease, the germinal centers showed productively infected T cells, i.e., CD4+CD1a-CD68- cells labeling intensely for HIV-1 RNA after in situ hybridization. The unenlarged nodes also showed extensive HIV-1 RNA retention on a well-preserved, follicular dendritic cell (FDC) network, and the follicles were abnormal. There were numerous CD8+ cells, many expressing TIA-1 granule antigen. Also, in contrast to normal follicles, CD4+ T cell proliferation was active, with marked increases in the number of cycling, Ki-67+CD4+CD45R0+ cells. After 28 d and 3 mo of therapy, productively infected T cells decreased dramatically and often were not apparent. The labeling of the FDC network for viral RNA also decreased, but not for gag protein. We conclude that HIV-1 replicates and accumulates in lymphoid organs before damage of the immune system, that at this stage of disease de novo production of T cells occurs in the lymphoid tissue, and that the infection is sensitive to triple drug therapy in both plasma and lymph nodes.
三联药物疗法对HIV-1感染的疗效促使其尽早使用,以防止免疫系统受损。我们监测了该疗法对12例病情轻微、病程为14 - 75个月的患者的影响,即CD4 +细胞计数持续>500/微升,且很少或没有淋巴结肿大。通过这种方式,我们首先可以确定疾病早期未肿大淋巴结中病毒复制的程度和免疫结构变化,其次可以同步跟踪血浆和淋巴组织对三联疗法的反应。正如已知的患有更晚期疾病的淋巴结一样,生发中心显示有高效感染的T细胞,即原位杂交后HIV-1 RNA强烈标记的CD4 + CD1a - CD68 -细胞。未肿大的淋巴结在保存完好的滤泡树突状细胞(FDC)网络上也显示出广泛的HIV-1 RNA滞留,并且滤泡异常。有大量CD8 +细胞,许多表达TIA-1颗粒抗原。此外,与正常滤泡相比,CD4 + T细胞增殖活跃,循环中的Ki-67 + CD4 + CD45R0 +细胞数量显著增加。治疗28天和3个月后,高效感染的T细胞显著减少,且通常不再明显。FDC网络对病毒RNA的标记也减少,但对gag蛋白的标记未减少。我们得出结论,HIV-1在免疫系统受损之前就在淋巴器官中复制和积累,在疾病的这个阶段淋巴组织中会发生T细胞的新生,并且该感染在血浆和淋巴结中对三联药物疗法敏感。